In a data-rich world, digital biomarkers have the potential to reduce costs, and improve patient outcomes. But what is a digital biomarker? Today we decided to take a look at the third and final topic that will feature in the HealthXL Global Gathering on February 22-23 in Basel Switzerland, Digital Biomarkers for Cognitive Disorders. We took a look at some of the innovations and companies that are developing the solutions of tomorrow, but first, what is a biomarker?

What is a Biomarker?

Simply put a biomarker is a measurable indicator of the severity or presence of some disease state. Thus, a digital biomarker is a measurable indicator of some disease state that is determined using a connected digital device. We decided to take a closer look at some of the companies and innovations in the space. Check it out below!

Why are we talking about it?

Cognitive disorders, often not well understood, are a disease category that has the potential to be impacted by digital biomarkers. Take for example a person with diagnosed with Parkinson’s Disease, they develop the disease from a complex interaction between their genotype and environment which leads to the parkinson’s phenotype: Tremor, Bradykinesia, postural instability. The beauty of digital biomarkers comes from when they can be deployed to objectively detect these phenotypes which can usually only be detected subjectively by a doctor later on in the progression of the disease. Check out three companies that we have found that are making strides within this nascent space:

Companies to watch that are innovating in the space

Neurotrack

Neurotrack’s first product, Imprint, released early this year, is a digital cognitive test that enables earlier and more effective evaluation of patients who may be at risk for cognitive decline. Imprint is a 5-minute web-based test that uses eye-tracking technology to assess brain function. Neurotrack has raised $8 million in funding to date and recently partnered with Welkin Health for a Study on Advanced Solutions for Individuals At Risk for Cognitive Decline.

neurotrack

Akilii

Akili is building a clinically validated, cognitive therapeutic assessment and diagnostic tool that looks and feels like a video game. Akili’s leading project, EVO is currently being evaluated in the STARS-ADHD study. They have raised $73 million in funding to date.

akili

NeuraMetrix

Neurametrix detects and monitors brain diseases, disorders, and injuries with non-invasive software that measures sub-clinical human cognitive and motor function based on typing cadence. The solution is so sensitive it notices inconsistencies in typing cadence that would usually go unnoticed by the naked eye.

neurametrix


HealthXL Global Gathering

February 22-23, 2017

Basel, Switzerland

We are delighted to announce that at our next HealthXL Global Gathering will take place in Basel Switzerland on February 23rd. One of the core topics of the event will be focused on Digital Biomarkers for Cognitive Disorders. Places are almost gone in this exclusive event, but if you would like to join us, make sure to register your interest through the link below.

Screen Shot 2016-12-12 at 23.19.57

Want to join us in the

HealthXL Global Gathering in Basel?

Apply Now for an Invitation

If you are an Investor, Startup, Healthcare Professional or Clinician, we want to hear from you.

Apply now to join the HealthXL Global Gathering in Basel on February 22-23.